Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL
- PMID: 17767167
- DOI: 10.1038/nm1627
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL
Abstract
Apo2L/TRAIL stimulates cancer cell death through the proapoptotic receptors DR4 and DR5, but the determinants of tumor susceptibility to this ligand are not fully defined. mRNA expression of the peptidyl O-glycosyltransferase GALNT14 correlated with Apo2L/TRAIL sensitivity in pancreatic carcinoma, non-small-cell lung carcinoma and melanoma cell lines, and up to 30% of samples from various human malignancies showed GALNT14 overexpression. RNA interference of GALNT14 reduced cellular Apo2L/TRAIL sensitivity, whereas overexpression increased responsiveness. Biochemical analysis of DR5 identified several ectodomain O-(N-acetyl galactosamine-galactose-sialic acid) structures. Sequence comparison predicted conserved extracellular DR4 and DR5 O-glycosylation sites; progressive mutation of the DR5 sites attenuated apoptotic signaling. O-glycosylation promoted ligand-stimulated clustering of DR4 and DR5, which mediated recruitment and activation of the apoptosis-initiating protease caspase-8. These results uncover a new link between death-receptor O-glycosylation and apoptotic signaling, providing potential predictive biomarkers for Apo2L/TRAIL-based cancer therapy.
Similar articles
-
Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.Cancer Res. 2006 Jun 1;66(11):5867-74. doi: 10.1158/0008-5472.CAN-05-3544. Cancer Res. 2006. PMID: 16740726
-
Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.Cancer Res. 2004 Jul 15;64(14):4900-5. doi: 10.1158/0008-5472.CAN-04-0408. Cancer Res. 2004. PMID: 15256461
-
TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.Mol Cancer Res. 2008 Dec;6(12):1861-71. doi: 10.1158/1541-7786.MCR-08-0313. Mol Cancer Res. 2008. PMID: 19074831
-
TRAIL death receptors and cancer therapeutics.Toxicol Appl Pharmacol. 2007 Nov 1;224(3):284-9. doi: 10.1016/j.taap.2006.12.007. Epub 2006 Dec 15. Toxicol Appl Pharmacol. 2007. PMID: 17240413 Review.
-
Targeting death-inducing receptors in cancer therapy.Oncogene. 2007 May 28;26(25):3745-57. doi: 10.1038/sj.onc.1210374. Oncogene. 2007. PMID: 17530027 Review.
Cited by
-
Glycobiology of cell death: when glycans and lectins govern cell fate.Cell Death Differ. 2013 Aug;20(8):976-86. doi: 10.1038/cdd.2013.50. Epub 2013 May 24. Cell Death Differ. 2013. PMID: 23703323 Free PMC article. Review.
-
Mesenchymal stem cells as vectors for lung cancer therapy.Respiration. 2013;85(6):443-51. doi: 10.1159/000351284. Epub 2013 May 23. Respiration. 2013. PMID: 23711430 Free PMC article. Review.
-
Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy.Antibodies (Basel). 2017 Oct 25;6(4):16. doi: 10.3390/antib6040016. Antibodies (Basel). 2017. PMID: 31548531 Free PMC article. Review.
-
The GALNT14 Genotype Predicts Postoperative Outcome of Pancreatic Ductal Adenocarcinoma.J Clin Med. 2019 Dec 16;8(12):2225. doi: 10.3390/jcm8122225. J Clin Med. 2019. PMID: 31888240 Free PMC article.
-
Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox.Cancers (Basel). 2019 Jul 31;11(8):1087. doi: 10.3390/cancers11081087. Cancers (Basel). 2019. PMID: 31370269 Free PMC article. Review.
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
